The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.00
Bid: 97.00
Ask: 98.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.031%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 98.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Shareholding/Share Incentive Plan

1 Sep 2021 07:00

RNS Number : 3003K
Diaceutics PLC
01 September 2021
 

 

1 September 2021

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR Shareholding/Share Incentive Plan

 

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified that on 27 August 2021 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted and Damian Thornton (both PDMRs), in respect of their purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

 

In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

 

 

Enquiries:

 

Diaceutics PLC 

 

Philip White, Chief Financial Officer 

Via Alma PR 

 

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

 

Stewart Wallace

 

Nick Adams

 

 

 

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Robyn Fisher

 

Kieran Breheny

 

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

a.

Position/Status

Managing Director and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

126

Conditional share award:

Price(s)

Volume(s)

Nil

252

e.

Date of the transaction

Share purchase and Conditional share award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Conditional share award: Off-Market

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Damian Thornton

2

Reason for notification

a.

Position/Status

Chief Operating Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

130

Options:

Price(s)

Volume(s)

Nil

260

 

 

e.

Date of the transaction

Share purchase and Option award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Option award: Off-Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKDBQFBKDPFN
Date   Source Headline
13th Mar 202310:12 amRNSFurther update regarding Silicon Valley Bank
13th Mar 20237:30 amRNSSuspension - Diaceutics PLC
13th Mar 20237:00 amRNSUpdate regarding Silicon Valley Bank
1st Mar 20231:57 pmRNSPDMR Shareholding/Share Incentive Plan
30th Jan 20235:11 pmRNSPDMR Shareholding/Share Incentive Plan
26th Jan 20237:00 amRNSUSD 7m enterprise engagements for data services
26th Jan 20237:00 amRNSTrading Statement and Strategy Update
3rd Jan 20237:00 amRNSPDMR Shareholding/Share Incentive Plan
29th Nov 20227:00 amRNSChange of Auditor
29th Nov 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Nov 20227:00 amRNSSub-optimal testing impacts on cancer patients
31st Oct 20222:20 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20225:03 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20227:00 amRNSPurchase of Shares and PDMR Shareholding
27th Sep 20227:00 amRNSHalf-year Report
12th Sep 202212:38 pmRNSPDMR Shareholding/Share Incentive Plan
8th Sep 20227:00 amRNSNotice of Results and Presentations
8th Aug 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
26th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Jul 20225:45 pmRNSPDMR Shareholding/Share Incentive Plan
13th Jun 20227:00 amRNSMulti-year contract with top five global pharma
7th Jun 20227:00 amRNSNew AI and ML Capabilities Enhance DXRX Platform
31st May 202212:12 pmRNSPDMR Shareholding/Share Incentive Plan
27th May 20224:31 pmRNSShare Options and PDMR Shareholdings
26th May 20223:00 pmRNSResult of AGM
11th May 20222:34 pmRNSPDMR Shareholding/Share Incentive Plan
9th May 20224:37 pmRNSExercise of Warrant & Total Voting Rights
5th May 20227:00 amRNSContract Win
29th Apr 20225:22 pmRNSPDMR Shareholding/Share Incentive Plan
28th Apr 20222:09 pmRNSNotice of AGM and Posting of Annual Report
7th Apr 20227:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
6th Apr 20221:13 pmRNSPDMR Shareholding/Share Incentive Plan
5th Apr 20223:49 pmRNSConversion of Convertible Loan Notes & TVR
1st Apr 20227:00 amRNSIssue of Share Options / PDMR Shareholdings
31st Mar 20225:38 pmRNSPDMR Shareholding/Share Incentive Plan
22nd Mar 20222:43 pmRNSFinal Results
22nd Mar 20227:00 amRNSNotice of 2021 Full Year Results
18th Mar 20222:09 pmRNSConfirmation of Directorate Change
16th Mar 20225:49 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSApproval by CMS for enhanced data access
2nd Mar 20225:37 pmRNSPDMR Shareholding/Share Incentive Plan
21st Feb 20227:00 amRNSInvestor Presentation
14th Feb 20226:26 pmRNSPDMR Shareholding/Share Incentive Plan
14th Feb 20227:00 amRNSContract with leading life sciences company
4th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Jan 20227:01 amRNSDirectorate Change
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.